C12N2795/10233

BACTERIOPHAGE TREATMENT AND REDUCTION IN INFLAMMATORY RESPONSE

The present invention relates to the treatment of bacterial infections and the reduction of inflammatory response using bacteriophage compositions. In an aspect, provided herein are methods of treating a bacterial infection characterized by inflammation in a subject, the method comprising administering to the subject a bacteriophage composition that is essentially free of impurities, wherein the composition reduces inflammation

BACTERIOPHAGE TREATMENT AND REDUCTION IN INFLAMMATORY RESPONSE
20220152131 · 2022-05-19 ·

The present invention relates to the treatment of bacterial infections and the reduction of inflammatory response using bacteriophage compositions. In an aspect, provided herein are methods of treating a bacterial infection characterized by inflammation in a subject, the method comprising administering to the subject a bacteriophage composition that is essentially free of impurities, wherein the composition reduces inflammation.

Bacteriophage strains and their applications

New strains of bacteriophages and their applications are revealed, useful especially in fish farming.

BACTERIOPHAGE STRAINS AND THEIR APPLICATIONS

New strains of bacteriophages and their applications are revealed, useful especially in fish farming.

NOVEL DNASE

The present invention relates to a group of proteins from bacterial phages which show DNA degrading activity.

Methods and compositions for treatment and control of plant disease

The present invention provides methods for development of a virulent bacteriophage-based treatment for the control of plant diseases caused by Xylella fastidiosa. The invention further provides methods of isolating and propagating bacteriophage virulent to X. fastidiosa in a Xanthomonas bacterial host and for treating or reducing symptoms of X. fastidiosa infection in a plant. The invention further provides methods of isolating and propagating bacteriophage virulent to Xanthomonas axonopodis pv. citri and for treating or reducing symptoms of Xanthomonas axonopodis pv. citri infection in a plant.

Method for treatment and control of plant disease

The present invention provides methods for development of a virulent bacteriophage-based treatment for the control of plant diseases caused by Xylella fastidiosa. The invention further provides methods of isolating and propagating bacteriophage virulent to X. fastidiosa in a Xanthomonas bacterial host and for treating or reducing symptoms of X. fastidiosa infection in a plant. The invention further provides methods of isolating and propagating bacteriophage virulent to Xanthomonas axonopodis pv. citri and for treating or reducing symptoms of Xanthomonas axonopodis pv. citri infection in a plant.

Polypeptides specific to Klebsiella pneumoniae capsular type strains
09938508 · 2018-04-10 · ·

The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.

Bacteriophage and antibacterial composition comprising the same

Provided is a novel bacteriophage CJ20 (KCCM11362P). In addition, the present invention relates to an antibacterial composition including the bacteriophage CJ20 (KCCM11362P) as an active ingredient. Further, the present invention is a method of preventing and/or treating infectious diseases by enterotoxigenic Escherichia coli in animals except for humans using the bacteriophage CJ20 (KCCM11362P) or the antibacterial composition containing the bacteriophage CJ20 (KCCM11362P) as an active ingredient.

POLYPEPTIDES AND BACTERIOPHAGES SPECIFIC TO KLEBSIELLA PNEUMONIAE CAPSULAR TYPE STRAINS
20170218344 · 2017-08-03 ·

The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.